全文获取类型
收费全文 | 438篇 |
免费 | 39篇 |
国内免费 | 2篇 |
专业分类
耳鼻咽喉 | 11篇 |
儿科学 | 3篇 |
妇产科学 | 4篇 |
基础医学 | 45篇 |
口腔科学 | 13篇 |
临床医学 | 36篇 |
内科学 | 108篇 |
皮肤病学 | 33篇 |
神经病学 | 30篇 |
特种医学 | 20篇 |
外科学 | 98篇 |
综合类 | 1篇 |
预防医学 | 26篇 |
眼科学 | 6篇 |
药学 | 15篇 |
肿瘤学 | 30篇 |
出版年
2023年 | 9篇 |
2022年 | 12篇 |
2021年 | 18篇 |
2020年 | 12篇 |
2019年 | 15篇 |
2018年 | 14篇 |
2017年 | 16篇 |
2016年 | 25篇 |
2015年 | 22篇 |
2014年 | 41篇 |
2013年 | 30篇 |
2012年 | 40篇 |
2011年 | 38篇 |
2010年 | 19篇 |
2009年 | 13篇 |
2008年 | 25篇 |
2007年 | 30篇 |
2006年 | 19篇 |
2005年 | 22篇 |
2004年 | 24篇 |
2003年 | 8篇 |
2002年 | 11篇 |
2001年 | 1篇 |
1999年 | 1篇 |
1996年 | 1篇 |
1994年 | 1篇 |
1992年 | 1篇 |
1990年 | 1篇 |
1989年 | 2篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1979年 | 1篇 |
1978年 | 1篇 |
排序方式: 共有479条查询结果,搜索用时 31 毫秒
21.
22.
23.
Mai Sato Shuichi Ito Masao Ogura Koichi Kamei Isao Miyairi Ippei Miyata Masataka Higuchi Kentaro Matsuoka 《Pediatric nephrology (Berlin, Germany)》2013,28(1):145-149
Background
Rituximab, an anti-CD20 antibody that targets B cells, is a promising agent against steroid-dependent and steroid-resistant nephrotic syndrome in children.Case-Diagnosis/Treatment
We report a 3-year-old boy who presented with atypical Pneumocystis jiroveci pneumonia (PCP) following administration of rituximab for refractory nephrotic syndrome. He had received cyclosporine and daily prednisolone for over 1?year. Following rituximab therapy, a hazy shadow was observed on his chest X-ray. Chest-computed tomography revealed multiple nodular lesions in bilateral lungs, although his clinical symptoms were subtle. PCR analysis demonstrated the presence of Pneumocystis DNA in his bronchoalveolar lavage. Lung wedge resection of the nodular lesion exhibited granulomas containing a few cysts of P. jiroveci that primarily consisted of T cells and histiocytes and lacked B cells. A deficiency of B cells following rituximab treatment suggests a dramatic effect on the immune response and, therefore, could result in granulomatous PCP. Nodular granulomatous lesions of PCP comprise an emerging concept previously reported in adults with hematological disease, bone marrow transplant, or treatment with rituximab. We report the first pediatric case of nodular PCP. Granulomatous PCP can be life-threatening. Moreover, bronchoalveolar lavage often fails to demonstrate the presence of P. jiroveci DNA. Wedge biopsy is warranted for definitive diagnosis. Our patient fully recovered with sulfamethoxazole/trimethoprim treatment because of early detection.Conclusions
The indication of rituximab for refractory nephrotic syndrome has increased recently. Therefore, recognition of the risk of atypical PCP is important. Our findings suggest that PCP prophylaxis should be considered following rituximab therapy. 相似文献24.
Kure-Hattori I Watari I Takei M Ishida Y Yonemitsu I Ono T 《Archives of oral biology》2012,57(7):987-994
Lubrication of synovial joints reduces the coefficient of friction of the articular cartilage surface. To investigate the effect of malocclusion on the lubrication of the temporomandibular joint (TMJ), we evaluated lubricin expression in the rat TMJ immunohistochemically, under conditions of functional lateral shift of the mandible, during period of growth. Thirty 5-week-old male Wistar rats were divided into experimental, recovery, and control groups. Each rt in the experimental and recovery groups was fitted with an acrylic-plate guiding appliance. The rats in the experimental and control groups were killed at 14 and 28 days after the appliance was attached. Each rat in the recovery group was detached from the appliance at 14 days, and was killed 14 days after the appliance was removed. In the experimental group, the expression of lubricin staining in TMJ cartilage was significantly decreased during the experimental period. In the recovery group, the expression of lubricin staining in TMJ cartilage was significantly greater than in the experimental group, and there was no significant difference at 28 days between the control and recovery groups. Analysis of these data suggests that a functional lateral shift of the mandible during the growth period influences lubrication of the TMJ. 相似文献
25.
Kokoro?KobayashiEmail author Yoshinori?Ito Masaaki?Matsuura Ippei?Fukada Rie?Horii Shunji?Takahashi Futoshi?Akiyama Takuji?Iwase Yasuo?Hozumi Yoshikazu?Yasuda Kiyohiko?Hatake 《Surgery today》2016,46(7):821-826
Purpose
Although improved long-term prognoses for patients with metastatic breast cancer (MBC) have been demonstrated, few reports address overall survival (OS) with sufficient follow-up. Furthermore, the relevance of immunohistological subtypes to OS in MBC has not been clarified.Methods
We evaluated, retrospectively, the OS of patients who had been initiated on systemic therapy for MBC between 2000 and 2008.Results
The subjects of this study were 527 patients with MBC treated by systemic therapy. The median survival time (MST) was 55.5 months. The MST for each immunohistological subtype was as follows: luminal, 59.9 months; luminal-HER2, not reached; triple-negative, 18.6 months; and HER2-enriched, 49.9 months. According to multivariate analysis, metastasis-free intervals of ≥2 years and treatment with anthracycline for MBC were predictive of better OS. The predictors of shorter OS included disease progression after first-line treatment for MBC, triple-negative, and all histological factors, except papillotubular carcinoma, with liver metastasis, and having three or more initial metastatic sites.Conclusions
The prognosis of the patients with MBC in this series was better than that reported before 2000, which is probably attributable to the use of novel, improved pharmacological agents. For example, luminal-HER2 tumors can be treated using both aromatase inhibitors and trastuzumab. Because of the lower toxicities, it is now possible to administer these agents for longer periods, resulting in better prognoses.26.
27.
28.
Sae Murakami Tetsuo Ajiki Kimihiko Ueno Hidehiro Sawa Shinobu Tsuchida Izuru Otsubo Yuko Yoshida Kenta Shinozaki Taro Okazaki Ippei Matsumoto Takumi Fukumoto Yonson Ku 《Surgery today》2014,44(7):1350-1354
A 25-year-old woman was referred to our hospital with persistent upper abdominal pain. Preoperative imaging studies revealed a hilar bile duct stricture with portal venous encasement, and the patient underwent curative resection involving extended left hepatectomy and segmental portal vein resection. The pathological findings demonstrated a well-differentiated tubular adenocarcinoma of the bile duct with regional lymph node metastasis (stage IIIB according to the UICC TNM classification), as well as the overexpression of p53 proteins and the K-ras gene mutation in tumor cells. The patient has shown no evidence of recurrence in the 10 months since the operation. Although there are several reports of relatively young adults with cholangiocarcinoma, the majority of such patients demonstrate either an anomalous arrangement of the pancreaticobiliary duct system or primary sclerosing cholangitis. The absence of any morphological abnormalities in this patient’s biliary system implicates de novo carcinogenesis as the most likely cause of the cholangiocarcinoma. 相似文献
29.
Takumi Fukumoto MD Masahiro Tominaga MD Masahiro Kido MD Atsushi Takebe MD Motofumi Tanaka MD Kaori Kuramitsu MD Ippei Matsumoto MD Tetsuo Ajiki MD Yonson Ku MD 《Annals of surgical oncology》2014,21(3):971-978
Background
Sorafenib is currently recommended as first-line therapy for patients with intermediate or advanced hepatocellular carcinoma (HCC) per Barcelona Clinic Liver Cancer staging. However, the median overall survival (OS) with sorafenib in these patients is 10.7 months with an overall response rate of 2 %. We retrospectively investigated the long-term outcomes and prognostic factors with reductive hepatectomy and sequential percutaneous isolated hepatic perfusion (PIHP) for refractory intermediate or advanced HCC.Methods
A total of 68 patients who had intermediate or advanced stage HCC without extrahepatic metastases were scheduled for reductive hepatectomy plus PIHP. All patients underwent reductive hepatectomy and PIHP with mitomycin C 20–40 mg/m2 and/or doxorubicin 60–120 mg/m2 1–3 months after surgery (mean, 1.51 times/patient).Results
The objective response rate of PIHP was 70.6 % (complete plus partial response). The median OS of all 68 patients was 25 months, and the 5-year OS rate was 27.6 %. Univariate and multivariate analyses indicated that tumor response to PIHP and normalization of serum des-γ-carboxy prothrombin concentrations after PIHP were independent prognostic factors for OS.Conclusions
The median OS of the study population treated by reductive hepatectomy and sequential PIHP was 25 months. This treatment strategy can offer a possible curative treatment to patients with refractory intermediate and advanced HCC. 相似文献30.